The lower of cost or market (LCM) method relies on the fact that when investors value a company’s inventory, those assets shall be recorded on the balance sheet at either the market value or the ...

Across both dose levels, NYX-2925 was well tolerated in the study, with no concerning safety issues observed. Detailed data from the study continue to be evaluated. About Aptinyx ...

(RTTNews) - Aptinyx Inc. (APTX) reported results from a phase 2b clinical study evaluating the effects of NYX-2925 in patients with painful diabetic peripheral neuropathy. NYX-2925 did not achieve ...

About NYX-2925. NYX-2925 is an investigational, novel oral NMDA receptor positive allosteric modulator (PAM) in Phase 2b clinical development for the treatment of chronic pain.